Loading...
Market
Story
GSK, Sanofi Face 75,000 Zantac Lawsuits, Shares Plunge 10%
Jun 3, 2024, 08:16 AM
A Delaware judge has ruled that GSK, Pfizer, and Sanofi must face approximately 75,000 lawsuits filed in state court regarding their former heartburn treatment, Zantac. The lawsuits allege that Zantac causes cancer, and the judge has allowed expert witnesses to testify in court. Following the ruling, GSK's shares tumbled by as much as 10% on Monday, marking their steepest decline in two years. GSK has announced plans to appeal the decision. The ruling has drawn significant media attention, and analysts suggest that GSK's potential liability could be substantial.
View original story
Similar markets
More than GSK and Pfizer combined • 50%
Less than GSK and Pfizer combined • 50%
Below $1 billion • 33%
$1 billion - $5 billion • 33%
Above $5 billion • 34%
Increase • 33%
Decrease • 33%
Remain stable • 34%
Less than 10% • 33%
10% to 20% • 33%
More than 20% • 33%
Increases • 33%
Decreases • 33%
Remains the same • 33%
Below £500 million • 25%
£500 million to £1 billion • 25%
£1 billion to £2 billion • 25%
Above £2 billion • 25%
Increase by >5% • 33%
Increase by ≤5% • 33%
Decrease • 33%